KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2015.33.15_suppl.tps4571
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Cancer
Cancer ResearchOncology
2010English

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
1999English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI‐Bevacizumab Versus FOLFOX‐Bevacizumab for Metastatic Colorectal Cancer (STEAM)

Oncologist
Cancer ResearchMedicineOncology
2019English

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Cancer
Cancer ResearchOncology
2009English

Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013

British Journal of Haematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy